How many stocks are there of Zomedica?
The current number of stocks of Zomedica is 979.95 M undefined.
Zomedica Stocks 2024
Zomedica Stocks
979.95 M
Ticker
ZOM
ISIN
CA98980M1095
WKN
A2QEF3
In 2024, Zomedica had 979.95 M outstanding stocks, a 0% change from the 979.95 M stocks in the previous year.
The Zomedica Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2026e | 979.95 |
| 2025e | 979.95 |
| 2024e | 979.95 |
| 2023 | 979.95 |
| 2022 | 979.92 |
| 2021 | 956.53 |
| 2020 | 364.44 |
| 2019 | 106.3 |
| 2018 | 93.44 |
| 2017 | 87.4 |
| 2016 | 80.16 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 0.34 |
| 2012 | 0.8 |
Zomedica shares outstanding CA98980M1095 · A2QEF3
The number of shares was Zomedica in 2023 — This indicates how many shares 979.95 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zomedica earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zomedica's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zomedica’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zomedica's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2012 | 800,000 Aktien |
| 2013 | 340,000 Aktien |
| 2014 | 1 M Aktien |
| 2015 | 1 M Aktien |
| 2016 | 80.16 M Aktien |
| 2017 | 87.4 M Aktien |
| 2018 | 93.44 M Aktien |
| 2019 | 106.3 M Aktien |
| 2020 | 364.44 M Aktien |
| 2021 | 956.53 M Aktien |
| 2022 | 979.92 M Aktien |
| 2023 | 979.95 M Aktien |
| 2024e | 979.95 M Aktien |
| 2025e | 979.95 M Aktien |
| 2026e | 979.95 M Aktien |
Zomedica Aktienanalyse
What does Zomedica do?
Zomedica Corp is an emerging company specializing in the development and marketing of innovative diagnostics and treatment options for pets. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica's business model is primarily focused on providing better diagnostics and therapy for pets to veterinarians and pet owners. The company develops and markets veterinary diagnostics and precise treatment solutions for various diseases in pets. Zomedica is divided into different divisions specializing in different areas of veterinary diagnostics and therapy. One of these divisions is "Point-of-Care" diagnostics, which allows veterinarians to perform quick and accurate diagnoses directly in their practice. Zomedica offers innovative devices and tests for the rapid diagnosis of diseases such as prostatitis or hypothyroidism. Another important division is "Companion Diagnostic" diagnostics, which is specifically focused on the diagnosis of cancer in pets. Zomedica has developed innovative tests that enable quick and precise diagnoses, allowing for targeted therapy initiation. In addition to diagnostics, Zomedica also offers innovative therapy solutions for pets. The company focuses on the development of antibiotics for animals, as well as precise treatment solutions for diseases such as diabetes or chronic kidney disease. One of Zomedica's best-known products is TRUFORMA, an innovative diagnostic device for veterinarians that enables quick and precise diagnosis of various diseases. The company has also developed a range of tests for the diagnosis of thyroid disease, prostatitis, and diabetes. In recent years, Zomedica has become one of the leading companies in veterinary diagnostics and therapy and has already convinced numerous veterinarians and pet owners of its innovative products and solutions. The company relies on close collaboration with veterinarians to continuously improve its products and tailor them to the needs of the market. Overall, Zomedica is an innovative company specializing in products and solutions for the needs of veterinarians and pet owners. With its innovative diagnostics and treatment solutions, the company is setting new standards in veterinary medicine and contributing to the improvement of pet health worldwide. Zomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Zomedica's Shares Outstanding
Zomedica's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Zomedica’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Zomedica’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Zomedica’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Zomedica stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Zomedica are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Zomedica evolved in recent years?
The number of shares of Zomedica has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Zomedica as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Zomedica?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Zomedica pay?
Over the past 12 months, Zomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zomedica is expected to pay a dividend of 0 USD.
What is the dividend yield of Zomedica?
The current dividend yield of Zomedica is .
When does Zomedica pay dividends?
Zomedica pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zomedica?
Zomedica paid dividends every year for the past 0 years.
What is the dividend of Zomedica?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zomedica located?
Zomedica is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zomedica kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zomedica from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did Zomedica pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of Zomedica in the year 2023?
In the year 2023, Zomedica distributed 0 USD as dividends.
In which currency does Zomedica pay out the dividend?
The dividends of Zomedica are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zomedica
Our stock analysis for Zomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
